Compare Genworth Financial Inc Common Stock (GNW) vs Eli Lilly And Co (LLY) Price & Performance

Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.

GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.

Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid a bullish technical outlook with strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights advancements in weight-loss and diabetes drugs, reinforcing growth prospects.

LLY's outlook remains positive, supported by a dominant position in obesity treatments and a promising pipeline. Risks include competitive pressures and high valuation multiples. Analyst consensus is strongly bullish with a $1,350 price target, though investors should monitor execution and regulatory developments.